Back to search
FDAFDA · Food and drugs·Recall number D-0840-2026

Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481-11).

Published September 9, 2026 · Recall initiated: August 19, 2026

Summary

FDA records drug Class III recall D-0840-2026, published September 9, 2026 and initiated August 19, 2026. Recalling firm: American Health Packaging; Status: Ongoing; Reported quantity: 10,953 cartons.; Lot: Lot # 1030023, Exp Date: 06/30/2027. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label Mix-up

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPRENORPHINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPRENORPHINE
Manufacturer
American Health Packaging
Distributor
US Nationwide.
Lot
Lot # 1030023, Exp Date: 06/30/2027.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481-11). recalled?

Yes. FDA published recall D-0840-2026 on September 9, 2026. Reported hazard: Labeling: Label Mix-up

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPRENORPHINE.